Zymeworks Inc. will participate in multiple investor conferences in September 2026, discussing its biotherapeutics pipeline and portfolio.
Quiver AI Summary
Zymeworks Inc., a biotechnology company focused on developing novel biotherapeutics, announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference, Citi’s Biopharma Back to School Summit, the Morgan Stanley Healthcare Conference, and the H.C. Wainwright Annual Global Investment Conference, all scheduled for September 2026. The management team will engage in one-on-one meetings and fireside chats to discuss the company's portfolio of licensed healthcare assets and its innovative pipeline aimed at treating challenging diseases such as cancer and autoimmune conditions. Zymeworks emphasizes its commitment to optimizing cash flows from its existing products, including its HER2-targeted bispecific antibody, Ziihera, and developing effective therapeutics through strategic partnerships. For more information, visit Zymeworks' website.
Potential Positives
- Participation in multiple prominent investor conferences raises Zymeworks' visibility within the biotechnology sector and among potential investors.
- The company is showcasing its innovative pipeline of biotherapeutics, which may attract interest and support from investors and partners.
- Strategic partnerships with global biopharmaceutical companies indicate a strong market position and collaborative efforts in advancing its therapeutic offerings.
- Zymeworks' focus on difficult-to-treat diseases and the development of high-value therapeutics demonstrates a commitment to addressing significant unmet medical needs, aligning with current healthcare trends.
Potential Negatives
- The press release does not provide any update on the company's financial performance or projections, which could raise concerns among investors regarding transparency and future growth potential.
- While highlighting participation in investor conferences, the release lacks information about significant recent developments or achievements in Zymeworks' drug pipeline, potentially indicating a lack of progress.
- There is no mention of any new partnerships or collaborations that could enhance their market position, suggesting a possible stagnation in their strategic initiatives.
FAQ
What upcoming investor conferences will Zymeworks participate in?
Zymeworks will participate in conferences including Wells Fargo on September 8 and Citi’s Biopharma Summit on September 9.
Where can I find information about Zymeworks' biotherapeutics?
Information about Zymeworks' pipeline of biotherapeutics can be found on their official website, www.zymeworks.com.
What is Zymeworks' core business focus?
Zymeworks focuses on developing and managing a portfolio of licensed healthcare assets and innovative biotherapeutics for difficult-to-treat diseases.
How does Zymeworks collaborate with other biopharmaceutical companies?
Zymeworks collaborates through strategic partnerships that leverage their therapeutic platforms and development capabilities to enhance product development.
What technologies does Zymeworks utilize in its drug development?
Zymeworks utilizes its proprietary Azymetric™ technology for developing differentiated antibody-based therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Revenue
$ZYME had revenues of $4.6M in Q2 2026. This is a decrease of -90.58% from the same period in the prior year.
You can track ZYME financials on Quiver Quantitative's ZYME stock page.
You can access data on ZYME stock through the Quiver Quantitative API.
$ZYME Hedge Fund Activity
We have seen 92 institutional investors add shares of $ZYME stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 1,680,121 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $42,070,229
- RUBRIC CAPITAL MANAGEMENT LP added 1,250,000 shares (+21.7%) to their portfolio in Q1 2026, for an estimated $31,300,000
- CITADEL ADVISORS LLC added 894,667 shares (+350.4%) to their portfolio in Q1 2026, for an estimated $22,402,461
- VESTAL POINT CAPITAL, LP removed 865,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $21,659,600
- MPM BIOIMPACT LLC added 565,249 shares (+inf%) to their portfolio in Q1 2026, for an estimated $14,153,834
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 564,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,122,560
- DEUTSCHE BANK AG\ removed 524,060 shares (-56.9%) from their portfolio in Q2 2026, for an estimated $13,698,928
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 6 analysts offer price targets for $ZYME in the last 6 months, with a median target of $46.5.
Here are some recent targets:
- Gregory Renza from Truist Securities set a target price of $31.0 on 07/07/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $37.0 on 06/30/2026
- Robert Burns from HC Wainwright & Co. set a target price of $46.0 on 06/03/2026
- Jonathan Miller from Evercore ISI Group set a target price of $48.0 on 03/09/2026
- Andrew Berens from Leerink Partners set a target price of $58.0 on 03/03/2026
- Stephen Willey from Stifel set a target price of $47.0 on 03/03/2026
Full Release
VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
- Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA.
- Citi’s Biopharma Back to School Summit: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY.
- Morgan Stanley Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 14 at 4:50 pm ET in New York, NY.
- H.C. Wainwright Annual Global Investment Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 15 in New York, NY.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
[email protected]
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
[email protected]
